TrialArthritis & rheumatology (Hoboken, N.J.)2019

A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Atul Deodhar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.